AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01805648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10\^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10\^9/L～100×10\^9/L.
Study NCT00553995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salsalate
Description: Salsalate 3-4 grams per day as tolerated for nine days
Study NCT00553995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03817918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Description: Patients undergoing thoracic surgery under general anesthesia using one-lung ventilation will have lung ultrasonography at 2 predetermined sites at four different time points
Study NCT04994925 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control ready meal
Description: Supermarket brand lasagne ready meal
Study NCT04994925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test ready meal
Description: The Slimming World lasagne ready meal
Study NCT03063749 — intervention group
Intervention type: DEVICE
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
Study NCT03063749 — intervention group
Intervention type: DEVICE
Intervention: Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
Description: Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
Study NCT00538642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone
Description: Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
Study NCT01608152 — intervention group
Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: Attend a focus group
Study NCT01608152 — intervention group
Intervention type: OTHER
Intervention: Internet-Based Intervention
Description: Have access to the game
Study NCT01608152 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: 1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
Study NCT01816087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brief geriatric assessment
Description: All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
Study NCT03411551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia
Description: The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
Study NCT03411551 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: regional anesthesia
Description: The analgesic effectivity of the forearm intravenous regional anesthesia and the ultrasound-guided peripheral nerve block will be investigated in patients undergoing carpal tunnel release
Study NCT04546698 — intervention group
Intervention type: OTHER
Intervention: blood sampling
Description: Analyse of expression modulation of 5-HT7 receptor in correlation with the immunological context, in 3 differents groups : 2 with multiple sclerosis patients, one healthy volunteers group
Study NCT02053116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05175157
Description: Tablet, 200 mg, twice daily, 6 weeks
Study NCT02053116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 0 mg, twice daily, 2 weeks
Study NCT02406612 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-Seal 6F Vascular Closure Device
Study NCT03737227 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Cinematographic recording
Description: Cinematographic recording during flexion and extension of the lumbar spine.
Study NCT02363660 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GINI
Study NCT00297414 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
Study NCT03022214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
Study NCT01812980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Inactivated Influenza Vaccine
Description: WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:~* an A/California/7/2009 (H1N1)pdm09-like virus;~* an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.
Study NCT01673347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meniscal Allograft
Description: Meniscal allograft
Study NCT02719873 — intervention group
Intervention type: OTHER
Intervention: The impact of maternal obesity on pregnancy outcomes
Description: observation of maternal obesity effect in foetal and maternal outcome
Study NCT00649311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
Study NCT00649311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
Study NCT03560739 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ofatumumab with PRF
Description: ofatumumab 20 mg subcutanious injection administered with pre-filled syringe (PRF)
Study NCT03560739 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: ofatumumab with AI
Description: ofatumumab 20 mg subcutaneous injection administered with autoinjector (AI)
Study NCT01936740 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Study NCT04474730 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BMT Physical Activity app
Description: This app sends reminders to patients, collect activity data from Apple Watch, and allow patients to submit symptoms.
Study NCT03544788 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cirvo™ Therapy
Description: The Cirvo(TM) (also referred to as the Radial Medical Compression System) is a mobile wearable medical device that applies graded intermittent mechanical sequential compression for the treatment of venous leg ulcers (VLU).
Study NCT04474730 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Watch Only
Description: A locked Apple Watch will be used to collect physical activity data from the Watch Only patients.
Study NCT04093830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aid
Description: hearing aid can be used in their non- implanted ear with residual hearing
Study NCT00559832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic Exposure
Description: Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
Study NCT02368925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultherapy™ System
Description: The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200\~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
Study NCT00177047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
Study NCT00177047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide + Mesna
Description: Cyclophosphamide: 4mg/m\^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
Study NCT00177047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Administered intravenously 200 mg/m\^2
Study NCT00177047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor
Description: Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
Study NCT01787344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A(Botox®)
Description: Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
Study NCT01787344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A(Botulax®)
Description: Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
Study NCT03505827 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 24-2 SITA Standard Humphrey Visual Field Test
Description: Patients participate in a 24-2 SITA Standard humphrey visual field test. This includes sitting in a dark room at a visual field machine. Stimulus test points of different intensity and size will be presented to the patient, as per SITA standard protocol. The patient will indicate by pressing a button when they see the visual stimulus.
Study NCT04769557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: tablet paracetamol 500 mg
Study NCT04769557 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00576680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Given orally once a day
Study NCT00576680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Taken orally once a day for one week followed by a one-week break period
Study NCT02230527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90mg twice a day by mouth
Study NCT02230527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75mg once a day by mouth
Study NCT01011478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Study NCT01011478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04643301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector
Description: Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery.
Study NCT03671278 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: STarT Back Screening Tool Approach
Description: Patients classified as low risk of persistent pain will be educated about their condition and how to manage their back pain by targeting modifiable prognostic factors. Patients classified as medium risk will receive evidence-based physical therapy. Patients classified as high risk will receive evidence-based physical therapy as well as individualized psychological intervention.
Study NCT04461600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL101
Description: AL101 is an inhibitor of gamma secretase-mediated Notch signaling.
Study NCT03933995 — intervention group
Intervention type: OTHER
Intervention: no Intervention
Description: no Intervention
Study NCT04403009 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03014882 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: L-Carnitine and N-acetyl cysteine
Study NCT03443557 — intervention group
Intervention type: OTHER
Intervention: oral nutrition supplement
Description: receiving prescription of oral nutrition supplement during hospitalization
Study NCT03721445 — intervention group
Intervention type: DEVICE
Intervention: continuous positive airway pressure
Description: Could the changes of HRV between PSG night and CPAP titration night predict the CPAP adherence?
Study NCT00246571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
Study NCT00246571 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.~1. Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks~2. Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles~3. Docetaxel - 75-100 mg/m2 every 3 weeks~4. Paclitaxel - 175-200 mg/m2 every 3 weeks~5. Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.~6. Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248.
Study NCT00775203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride (HCl) Extended-Release Tablets
Study NCT00775203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00941434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RUTF
Description: Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
Study NCT00232869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-eluting stent
Description: Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
Study NCT00232869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare-metal stent
Description: SMART™ bare-metal stent
Study NCT02307253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)
Description: EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
Study NCT05343533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
Study NCT05343533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: After baseline or initial testing, participants will be randomly assigned in a double-blind fashion to ingest on a daily basis for 6 weeks either a placebo or a probiotic supplement. Identical follow-up measurements will then occur each visit after taking their assigned supplement. After 6 weeks of administration, the supplementation protocol will stop and a final evaluation will be completed 3 weeks later (9 weeks after initial administration) to assess any residual impact of the assigned supplement after a 3-week washout.
Study NCT00628043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta
Description: Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
Study NCT00628043 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous administration of placebo once-weekly for 12 weeks
Study NCT00275821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3 mg - 3 times monthly, then quarterly
Description: Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
Study NCT00275821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg - 3 times monthly, then quarterly
Description: Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
Study NCT03022214 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:~* EnduraCell broccoli sprout powder: 3 capsules~* Bulk Powders Green tea extract: 1 capsule~* Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
Study NCT03107195 — intervention group
Intervention type: DRUG
Intervention: Imaging Time
Description: Participants will be asked to be imaged at an additional time point.
Study NCT03704337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially Available Food Bar
Description: Active
Study NCT03704337 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04708912 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: The study parameters will be obtained at the time of recuirement (Basal)
Study NCT00986531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8529
Description: 2 capsules by mouth for 3 days
Study NCT00986531 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match AZD8529
Description: 2 capsules by mouth for 3 days
Study NCT00538681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 milligrams (mg) loading dose then 500 mg, oral (po), daily (QD), until disease progression
Study NCT00538681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
Study NCT00538681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: 500 milligrams/square meter (mg/m²), intravenously (IV), every 21 days, for each 21-day cycle
Study NCT00538681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m², IV, every 21 days, for each 21-day cycle
Study NCT00538681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: 75 mg/m², IV, every 21 days, for each 21-day cycle
Study NCT00538681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po, QD
Study NCT01905956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: IQP-AK-102
Description: IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
Study NCT01905956 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
Study NCT01106755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait training on ground level using BWS
Description: An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
Study NCT01106755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gait training on ground level using BWS associated to FES
Description: An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
Study NCT02792257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol (Marinol®)
Description: 5mg - 10mg daily dose
Study NCT02792257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose